Product Information
CHILDREN IBUPROFEN 100 MG/5 ML is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.0332 per ML under NDC 45802014026. Its NADAC has been published 639 times since Jul 9, 2014.
FDA first approved this application on Dec 22, 1998.
Strength
100 mg/5mL
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802014026
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA074937FDA Approved
12/22/1998
On Market Since
4/9/2014
Pharmacological Classes
Price Statistics
The NADAC for CHILDREN IBUPROFEN 100 MG/5 ML has been published 639 times since Jul 9, 2014, and over the history we have for it it has risen 26.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0332 per ML |
|---|---|
| All-time high | $0.0394 (Dec 13, 2023) |
| All-time low | $0.0236 (Jan 19, 2022) |
| 52-week high | $0.0358 |
| 52-week low | $0.0332 |
| Median price | $0.0287 |
| Average price | $0.0302 |
| Largest weekly change | +42.7% (Mar 22, 2023) |
| Weeks tracked | 639 |
| Tracking since | Jul 9, 2014 |
Generic Alternatives
The matcher finds 10 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 29% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CHILDREN IBUPROFEN 100 MG/5 ML?
The current National Average Drug Acquisition Cost (NADAC) for CHILDREN IBUPROFEN 100 MG/5 ML, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.0332 per ML (NDC 45802014026), effective Sep 30, 2026.
How has the price of CHILDREN IBUPROFEN 100 MG/5 ML changed over time?
Over the history we have for it, the NADAC for CHILDREN IBUPROFEN 100 MG/5 ML has risen 26.7%. It has been tracked across 639 weekly CMS publications since Jul 9, 2014.
What are the highest and lowest recorded NADAC prices for CHILDREN IBUPROFEN 100 MG/5 ML?
Since Jul 9, 2014, the NADAC for CHILDREN IBUPROFEN 100 MG/5 ML has ranged from a low of $0.0236 (Jan 19, 2022) to a high of $0.0394 (Dec 13, 2023), with a median of $0.0287 per ML.
Are there cheaper alternatives to CHILDREN IBUPROFEN 100 MG/5 ML?
Yes. 10 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CHILDREN IBUPROFEN 100 MG/5 ML, is $0.0237 per ML — about 29% below CHILDREN IBUPROFEN 100 MG/5 ML.
Who manufactures CHILDREN IBUPROFEN 100 MG/5 ML?
CHILDREN IBUPROFEN 100 MG/5 ML (NDC 45802014026) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.